ENTA
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops oral small molecule drugs for virology and immunology indications. In virology, the company focuses on respiratory syncytial virus (RSV), with clinical-stage candidates zelicapavir and EDP-323, and maintains programs for SARS-CoV-2 and Hepatitis B virus. Its immunology pipeline targets type 2 inflammatory diseases, including atopic dermatitis and chronic spontaneous urticaria, through inhibitors of KIT, STAT6, and MRGPRX2. Enanta previously collaborated with AbbVie to discover glecaprevir and paritaprevir, which are marketed as part of the direct-acting antiviral regimens MAVYRET and VIEKIRA PAK for chronic hepatitis C virus infection. The company was founded in 1995 and serves patients in the United States and international markets.

Summarised from the company's own disclosures, fiscal year ended Nov 2025

Industry Biotechnology Homepage enanta.com
Sector Healthcare IR page ir.enanta.com
Tags
virology, immunology, small molecule drugs, respiratory syncytial virus, hepatitis c, hepatitis b, sars-cov-2, atopic dermatitis, urticaria, oral therapeutics, glecaprevir, paritaprevir, MAVYRET, VIEKIRA PAK, zelicapavir, EDP-938, EDP-323, EDP-978, EDP-235, EDP-514
Press page —

Metrics

Valuation  
Market cap $ 384.092M
Market cap (USD) $ 384.092M
P/E -5.61
PEG —
P/BV 4.79
P/S 6.10
P/OCF -9.02
P/FCF -8.98
Dividend yield —
Turnover / mcap —
Returns  
ROE -94.2%
ROI -61.7%
ROIC -42.3%
Profit margin -108.3%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 23
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 63.001M 65.324M 67.635M 79.204M 86.16M 97.074M 122.473M 205.197M 206.625M 102.814M 88.268M 160.88M 47.741M 32.053M 41.706M
Net profit -68.248M -81.889M -116.045M -133.816M -121.755M -78.996M -36.168M 46.383M 71.956M 17.71M 21.666M 78.992M 34.438M 9.627M 21.399M
Free cash flow -42.766M -32.168M -96.712M -112.212M -86.907M -70.746M 5.643M 66.001M 26.239M 50.147M 31.071M 74.337M 19.151M 10.047M 22.371M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 13.18 11.97 10.36 11.17 51.87 56.81 45.78 60.08 85.46 46.8 26.61 36.14 39.57 22.92 —
Price performance 12m 0.1 0.16 -0.07 -0.78 -0.09 0.24 -0.24 -0.3 0.83 0.76 -0.26 -0.09 0.73 — —

Filed figures

Figure Sep 2017 Sep 2018 Sep 2019 Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025 Sep 2026
Balance sheet detail
Trade receivables (USD) 10.6M 67.2M 51.3M 23.5M 23.6M 20.3M 8.61M 6.65M 6.88M 5.86M
↳ YoY growth -17.3% +533.2% -23.6% -54.2% +0.4% -13.8% -57.6% -22.8% +3.6% -14.9%
↳ 5y CAGR +58.9% +142.1% +97.1% +9.0% +12.9% +13.9% -33.7% -33.6% -21.8% -24.3%
Lease liabilities (USD) — — 8.62M 8.1M 5.33M 25.3M 26.5M 55.5M 57.9M 54.8M
Cash and deposits (USD) 65.7M 63.9M 51.2M 87.1M 57.2M 44M 85.4M 37.2M 32.3M 20.3M
Right-of-use assets (USD) — — 7.15M 7.02M 4.71M 23.6M 22.8M 40.7M 37.5M 35.2M
Cash flow detail
Operating cash flow (USD) 52.7M 29.2M 71.4M 7.09M -70M -84.8M -103M -78.8M -19.3M -42.6M
Purchases of property, plant and equipment (USD) -2.51M -2.98M -5.42M -1.45M -750,000 -2.13M -9.06M -17.9M -12.9M -206,000
Change in receivables (cash effect) (USD) 2.23M -56.6M 15.9M 27.8M -84,000 3.26M 11.7M 1.97M -236,000 1.03M
Change in payables (cash effect) (USD) 633,000 1.32M 1.79M -883,000 3.77M -4.63M -1.15M -414,000 -1.31M 763,000
Interest paid (cash effect) (USD) — — — — — 0.00 -1.99M -11.7M -8.79M -12.9M
Income taxes paid (cash effect) (USD) -1.59M -26.1M -12.7M -105,000 -32,000 0.00 -4.9M -241,000 -109,000 0.00
Share-based compensation (USD) 13.1M 15.8M 19.2M 19.6M 21M 27M 28.2M 26.8M 18.6M 14M
Operating cash flow before change in receivables (USD) 50.4M 85.8M 55.5M -20.7M -69.9M -88M -115M -80.7M -19M -43.6M
Free cash flow (OCF - PPE - intangibles) (USD) 50.1M 26.2M 66M 5.64M -70.7M -86.9M -112M -96.7M -32.2M -42.8M
Income detail
Research and development expense (USD) 57.5M 94.9M 142M 137M 174M 165M 164M 131M 107M 88.5M
↳ 5y CAGR +30.6% +41.3% +50.0% +42.6% +33.9% +23.4% +11.5% -1.6% -4.8% -12.6%
Total comprehensive income (USD) 17.6M 71.7M 46.9M -35.5M -80.2M -125M -131M -115M -82.5M -68.9M
Comprehensive income to owners (USD) 17.6M 71.7M 46.9M -35.5M -80.2M -125M -131M -115M -82.5M -68.9M
Reported Dec 11, 2017 Nov 29, 2018 Feb 10, 2020 Nov 25, 2020 Nov 24, 2021 Nov 27, 2024 Nov 27, 2024 Nov 27, 2024 Nov 19, 2025 Nov 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q 2027

•Initiated Dosing in RESOLVE, a Phase 2b/3 Trial of Zelicapavir in Adult Patients at High-Risk of Severe RSV Outcomes; Topline Phase 2b Data Expected in 2027

•Topline Data from Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, Now Expected in 1Q 2027

•Investigational New Drug (IND) Application Filing for EDP-903, an Oral, Once-Daily STAT6 Inhibitor, Now Expected in 2Q 2027

•Selected MRGPRX2 Development Candidate EPS-5336 for the Treatment of Mast Cell-Driven Diseases Including Migraine; IND Filing Targeted for 4Q 2027

•Announced the Planned Retirement of Longstanding President and Chief Executive Officer, Jay R. Luly, Ph.D. by February 2027, and the Promotion of Tara L. Kieffer, Ph.D. to Chief Operating Officer

•Cash and Marketable Securities Totaling $194.5 Million at September 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029

WATERTOWN, Mass., November 16, 2026 – Enanta Pharmaceuticals, Inc.

Nov 04, 2026

PDF Version

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 4, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences.

  • **2026 Jefferies Global Healthcare Conference in London:**Fireside Chat on Wednesday, November 18, 2026, at 2:30 p.m. GMT / 9:30 a.m. EST

  • 9th Annual Evercore Healthcare Conference: Fireside Chat on Wednesday, December 2, 2026, at 10:25 a.m. EST

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcasts will be available following the presentation and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104949253/en/

Media and Investors Contact Jennifer Viera 617-744-3848 [email protected]

Source: Enanta Pharmaceuticals, Inc.

MENU

Enanta Pharmaceuticals, Inc. — Other Events Bull 0 Bear 6 Legal

As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 (the “‘265 Patent”) in connection with Pfizer’s manufacture, use, and sale of Paxlovid™ (nirmatrelvir tablets; ritonavir tablets) in the 18 EU member states participating in the UPC. Pfizer counterclaimed for revocation of the ’265 Patent. A hearing on the infringement action and counterclaim for revocation was held on September 29, 2026. On October 29, 2026, the UPC released its decision concluding that the ‘265 Patent is invalid. The UPC also determined that the infringement action was unfounded in light of its decision on validity.

Prompts

Enanta Pharmaceuticals, Inc. (ticker ENTA), listed in United States.

ETFs Holding Enanta Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
FSML 0.10% 8,204 $ 119.614K Jun 30, 2026
FSEV 0.07% 340 $ 4,957.20 Jun 30, 2026
FSEG 0.06% 252 $ 3,674.16 Jun 30, 2026
FEAC 0.06% 1,083 $ 15.79K Jun 30, 2026
VFMO 0.03% 42,000 $ 559.86K Aug 31, 2026
DFAS 0.00% 127,336 $ 1.426M Nov 12, 2026
DXUV 0.00% 6,032 $ 67.558K Nov 12, 2026
DFAU 0.00% 4,851 $ 54.331K Nov 12, 2026
DFUS 0.00% 3,542 $ 39.67K Nov 12, 2026
DCOR 0.00% 6,218 $ 69.642K Nov 12, 2026
DFAC 0.00% 6,069 $ 67.973K Nov 12, 2026
AVSU 0.00% 62 $ 661.54 Nov 16, 2026